Andrea G. Hohmann - Publications

Affiliations: 
Psychological & Brain Sciences Indiana University, Bloomington, Bloomington, IN, United States 
Area:
cannabinoid pharmacology
Website:
http://www.indiana.edu/~alldrp/members/hohmann.html

90 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Iyer V, Saberi SA, Pacheco R, Sizemore EF, Stockman S, Kulkarni A, Cantwell L, Thakur GA, Hohmann AG. Negative allosteric modulation of CB cannabinoid receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception. Neuropharmacology. 257: 110052. PMID 38936657 DOI: 10.1016/j.neuropharm.2024.110052  0.334
2024 Iyer V, Saberi SA, Pacheco R, Sizemore EF, Stockman S, Kulkarni A, Cantwell L, Thakur GA, Hohmann AG. Negative allosteric modulation of cannabinoid CB receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception. Biorxiv : the Preprint Server For Biology. PMID 38260598 DOI: 10.1101/2024.01.06.574477  0.317
2023 Guenther KG, Xu Z, Romero J, Hillard CJ, Mackie K, Hohmann AG. Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain. Neuropharmacology. 109601. PMID 37286073 DOI: 10.1016/j.neuropharm.2023.109601  0.36
2021 Lin X, Xu Z, Carey L, Romero J, Makriyannis A, Hillard CJ, Ruggiero E, Dockum M, Houk G, Mackie K, Albrecht PJ, Rice FL, Hohmann AG. A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse. Pain. PMID 35001054 DOI: 10.1097/j.pain.0000000000002502  0.301
2020 Iyer V, Slivicki RA, Thomaz AC, Crystal JD, Mackie K, Hohmann AG. The cannabinoid CB receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence. European Journal of Pharmacology. 886: 173544. PMID 32896549 DOI: 10.1016/J.Ejphar.2020.173544  0.398
2020 Slivicki RA, Iyer V, Mali SS, Garai S, Thakur GA, Crystal JD, Hohmann AG. Positive Allosteric Modulation of CB Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward. Frontiers in Molecular Neuroscience. 13: 54. PMID 32410959 DOI: 10.3389/Fnmol.2020.00054  0.408
2019 Garai S, Kulkarni PM, Schaffer PC, Leo L, Brandt AL, Zagzoog A, Black T, Lin X, Hurst DP, Janero DR, Abood ME, Zimmowitch A, Straiker A, Pertwee RG, Kelly M, ... ... Hohmann A, et al. Application of Fluorine- And Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of CB1 Receptor Positive Allosteric Modulators. Journal of Medicinal Chemistry. PMID 31756109 DOI: 10.1021/Acs.Jmedchem.9B01142  0.387
2019 Slivicki RA, Mali SS, Hohmann AG. Voluntary exercise reduces both chemotherapy-induced neuropathic nociception and deficits in hippocampal cellular proliferation in a mouse model of paclitaxel-induced peripheral neuropathy. Neurobiology of Pain (Cambridge, Mass.). 6: 100035. PMID 31528755 DOI: 10.1016/j.ynpai.2019.100035  0.399
2019 Ferris CF, Nodine S, Pottala T, Cai X, Knox TM, Fofana FH, Kim S, Kulkarni P, Crystal JD, Hohmann AG. Alterations in brain neurocircuitry following treatment with the chemotherapeutic agent paclitaxel in rats. Neurobiology of Pain (Cambridge, Mass.). 6: 100034. PMID 31223138 DOI: 10.1016/J.Ynpai.2019.100034  0.381
2019 Slivicki RA, Xu Z, Mali SS, Hohmann AG. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance, physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro. Pharmacological Research. PMID 30739035 DOI: 10.1016/j.phrs.2019.02.002  0.385
2018 Li AL, Lin X, Dhopeshwarkar AS, Thomaz AC, Carey LM, Liu Y, Nikas SP, Makriyannis A, Mackie K, Hohmann AG. The cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal. Molecular Pharmacology. PMID 30504240 DOI: 10.1124/Mol.118.113233  0.485
2018 Slivicki RA, Saberi SA, Iyer V, Vemuri K, Makriyannis A, Hohmann AG. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase synergize with the opioid analgesic morphine to suppress chemotherapy-induced neuropathic nociception without enhancing effects of morphine on gastrointestinal transit. The Journal of Pharmacology and Experimental Therapeutics. PMID 30275151 DOI: 10.1124/Jpet.118.252288  0.431
2018 Liu Y, Ji L, Eno M, Kudalkar S, Li A, Schimpgen M, Benchama O, Morales P, Xu S, Hurst DP, Wu S, Mohammad KA, Wood JT, Zvonok N, Papahatjis D, ... ... Hohmann A, et al. (R)-N-(1-Methyl-2-hydroxyethyl)-13-(S)-methyl-arachidonamide (AMG315): A Novel Chiral Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes. Journal of Medicinal Chemistry. PMID 30196704 DOI: 10.1021/Acs.Jmedchem.8B00611  0.331
2018 Lee WH, Carey LM, Li LL, Xu Z, Lai YY, Courtney MJ, Hohmann A. [EXPRESS] ZLc002, a putative small molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability. Molecular Pain. 1744806918801224. PMID 30157705 DOI: 10.1177/1744806918801224  0.301
2018 Lee WH, Li LL, Chawla A, Hudmon A, Lai YY, Courtney MJ, Hohmann AG. Disruption of nNOS-NOS1AP protein-protein interactions suppresses neuropathic pain in mice. Pain. PMID 29319606 DOI: 10.1097/J.Pain.0000000000001152  0.423
2017 Lin X, Dhopeshwarkar AS, Huibregtse M, Mackie K, Hohmann AG. The slowly signaling G protein-biased CB2 cannabinoid receptor agonist LY2828360 suppresses neuropathic pain with sustained efficacy and attenuates morphine tolerance and dependence. Molecular Pharmacology. PMID 29192123 DOI: 10.1124/Mol.117.109355  0.418
2017 Slivicki RA, Xu Z, Kulkarni PM, Pertwee RG, Mackie K, Thakur GA, Hohmann AG. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. Biological Psychiatry. PMID 28823711 DOI: 10.1016/J.Biopsych.2017.06.032  0.456
2017 Woodhams SG, Chapman V, Finn DP, Hohmann AG, Neugebauer V. The cannabinoid system and pain. Neuropharmacology. PMID 28625720 DOI: 10.1016/J.Neuropharm.2017.06.015  0.373
2017 Li AL, Carey LM, Mackie K, Hohmann AG. The cannabinoid CB2 agonist GW405833 suppresses inflammatory and neuropathic pain through a CB1 mechanism that is independent of CB2 receptors in mice. The Journal of Pharmacology and Experimental Therapeutics. PMID 28592614 DOI: 10.1124/Jpet.117.241901  0.471
2017 Carey LM, Gutierrez T, Deng L, Lee WH, Mackie K, Hohmann AG. Inflammatory and Neuropathic Nociception is Preserved in GPR55 Knockout Mice. Scientific Reports. 7: 944. PMID 28428628 DOI: 10.1038/s41598-017-01062-2  0.403
2017 Carey LM, Lee WH, Gutierrez T, Kulkarni PM, Thakur GA, Lai YY, Hohmann AG. Small molecule inhibitors of PSD95-nNOS protein-protein interactions suppress formalin-evoked Fos protein expression and nociceptive behavior in rats. Neuroscience. PMID 28285942 DOI: 10.1016/j.neuroscience.2017.02.055  0.327
2016 Deng L, Lee WH, Xu Z, Makriyannis A, Hohmann AG. Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems. Pharmacological Research. PMID 27773824 DOI: 10.1016/J.Phrs.2016.10.007  0.442
2016 Carey LM, Slivicki RA, Leishman E, Cornett B, Mackie K, Bradshaw H, Hohmann AG. A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase. Molecular Pain. 12. PMID 27178246 DOI: 10.1177/1744806916649192  0.435
2016 Slivicki RA, Ali YO, Lu HC, Hohmann AG. Impact of Genetic Reduction of NMNAT2 on Chemotherapy-Induced Losses in Cell Viability In Vitro and Peripheral Neuropathy In Vivo. Plos One. 11: e0147620. PMID 26808812 DOI: 10.1371/Journal.Pone.0147620  0.313
2015 Lee WH, Xu Z, Ashpole NM, Hudmon A, Kulkarni PM, Thakur GA, Lai YY, Hohmann AG. Small molecule inhibitors of PSD95-nNOS protein-protein interactions as novel analgesics. Neuropharmacology. PMID 26071110 DOI: 10.1016/J.Neuropharm.2015.05.038  0.385
2015 Marcus DJ, Zee M, Hughes A, Yuill MB, Hohmann AG, Mackie K, Guindon J, Morgan DJ. Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase. Molecular Pain. 11: 34. PMID 26065412 DOI: 10.1186/s12990-015-0031-4  0.431
2015 Deng L, Cornett BL, Mackie K, Hohmann AG. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain. Molecular Pharmacology. 88: 64-74. PMID 25904556 DOI: 10.1124/mol.115.098483  0.45
2015 Deng L, Guindon J, Cornett BL, Makriyannis A, Mackie K, Hohmann AG. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal. Biological Psychiatry. 77: 475-87. PMID 24853387 DOI: 10.1016/j.biopsych.2014.04.009  0.444
2014 Piomelli D, Hohmann AG, Seybold V, Hammock BD. A lipid gate for the peripheral control of pain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 15184-91. PMID 25392487 DOI: 10.1523/Jneurosci.3475-14.2014  0.413
2014 Guindon J, Deng L, Fan B, Wager-Miller J, Hohmann AG. Optimization of a cisplatin model of chemotherapy-induced peripheral neuropathy in mice: use of vitamin C and sodium bicarbonate pretreatments to reduce nephrotoxicity and improve animal health status. Molecular Pain. 10: 56. PMID 25189223 DOI: 10.1186/1744-8069-10-56  0.373
2014 Rahn EJ, Deng L, Thakur GA, Vemuri K, Zvonok AM, Lai YY, Makriyannis A, Hohmann AG. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery. Molecular Pain. 10: 27. PMID 24742127 DOI: 10.1186/1744-8069-10-27  0.749
2014 Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management. 47: 166-73. PMID 23742737 DOI: 10.1016/j.jpainsymman.2013.02.018  0.363
2013 Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacological Research : the Official Journal of the Italian Pharmacological Society. 67: 94-109. PMID 23127915 DOI: 10.1016/j.phrs.2012.10.013  0.501
2012 Deng L, Guindon J, Vemuri VK, Thakur GA, White FA, Makriyannis A, Hohmann AG. The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CBâ‚‚ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. Molecular Pain. 8: 71. PMID 22998838 DOI: 10.1186/1744-8069-8-71  0.492
2012 Gregg LC, Jung KM, Spradley JM, Nyilas R, Suplita RL, Zimmer A, Watanabe M, Mackie K, Katona I, Piomelli D, Hohmann AG. Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 9457-68. PMID 22787031 DOI: 10.1523/Jneurosci.0013-12.2012  0.422
2011 Sciolino NR, Zhou W, Hohmann AG. Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacological Research : the Official Journal of the Italian Pharmacological Society. 64: 226-34. PMID 21600985 DOI: 10.1016/J.Phrs.2011.04.010  0.771
2011 Gutierrez T, Crystal JD, Zvonok AM, Makriyannis A, Hohmann AG. Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain. 152: 1976-87. PMID 21550725 DOI: 10.1016/J.Pain.2011.03.038  0.4
2011 Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, Hohmann AG. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacology, Biochemistry, and Behavior. 98: 493-502. PMID 21382397 DOI: 10.1016/J.Pbb.2011.02.024  0.729
2011 Guindon J, Guijarro A, Piomelli D, Hohmann AG. Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. British Journal of Pharmacology. 163: 1464-78. PMID 21198549 DOI: 10.1111/j.1476-5381.2010.01192.x  0.447
2011 Sciolino N, Bortolato M, Eisenstein S, Fu J, Oveisi F, Hohmann A, Piomelli D. SOCIAL ISOLATION AND CHRONIC HANDLING ALTER ENDOCANNABINOID SIGNALING AND BEHAVIORAL REACTIVITY TO CONTEXT IN ADULT RATS (vol 168, pg 371, 2010) Neuroscience. 187: 103-103. DOI: 10.1016/J.Neuroscience.2011.04.071  0.735
2010 Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, Tontini A, Sanchini S, Sciolino NR, Spradley JM, Hohmann AG, Calignano A, Mor M, Tarzia G, Piomelli D. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nature Neuroscience. 13: 1265-70. PMID 20852626 DOI: 10.1038/Nn.2632  0.788
2010 Spradley JM, Guindon J, Hohmann AG. Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Pharmacological Research : the Official Journal of the Italian Pharmacological Society. 62: 249-58. PMID 20416378 DOI: 10.1016/j.phrs.2010.03.007  0.424
2010 Sciolino NR, Bortolato M, Eisenstein SA, Fu J, Oveisi F, Hohmann AG, Piomelli D. Social isolation and chronic handling alter endocannabinoid signaling and behavioral reactivity to context in adult rats. Neuroscience. 168: 371-86. PMID 20394803 DOI: 10.1016/J.Neuroscience.2010.04.007  0.752
2010 Rahn EJ, Zvonok AM, Makriyannis A, Hohmann AG. Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation. The Aaps Journal. 12: 147-57. PMID 20127295 DOI: 10.1208/S12248-009-9170-8  0.714
2010 Eisenstein SA, Clapper JR, Holmes PV, Piomelli D, Hohmann AG. A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy. Pharmacological Research : the Official Journal of the Italian Pharmacological Society. 61: 419-29. PMID 20044005 DOI: 10.1016/J.Phrs.2009.12.013  0.621
2009 Guindon J, Hohmann AG. The endocannabinoid system and pain. Cns & Neurological Disorders Drug Targets. 8: 403-21. PMID 19839937 DOI: 10.2174/187152709789824660  0.481
2009 Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 713-37. PMID 19789075 DOI: 10.1016/J.Nurt.2009.08.002  0.725
2009 Eisenstein SA, Holmes PV, Hohmann AG. Endocannabinoid modulation of amphetamine sensitization is disrupted in a rodent model of lesion-induced dopamine dysregulation. Synapse (New York, N.Y.). 63: 941-50. PMID 19593824 DOI: 10.1002/Syn.20679  0.622
2009 Nyilas R, Gregg LC, Mackie K, Watanabe M, Zimmer A, Hohmann AG, Katona I. Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. The European Journal of Neuroscience. 29: 1964-78. PMID 19453631 DOI: 10.1111/J.1460-9568.2009.06751.X  0.438
2009 Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Research Reviews. 60: 255-66. PMID 19150370 DOI: 10.1016/j.brainresrev.2008.12.003  0.49
2008 Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. The Journal of Pharmacology and Experimental Therapeutics. 327: 584-91. PMID 18664590 DOI: 10.1124/Jpet.108.141994  0.765
2008 Moise AM, Eisenstein SA, Astarita G, Piomelli D, Hohmann AG. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology. 200: 333-46. PMID 18545985 DOI: 10.1007/S00213-008-1209-5  0.422
2008 Guindon J, Hohmann AG. A physiological role for endocannabinoid-derived products of cyclooxygenase-2-mediated oxidative metabolism. British Journal of Pharmacology. 153: 1341-3. PMID 18297102 DOI: 10.1038/bjp.2008.41  0.321
2008 Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. British Journal of Pharmacology. 153: 319-34. PMID 17994113 DOI: 10.1038/sj.bjp.0707531  0.497
2008 Suplita RL, Eisenstein SA, Neely MH, Moise AM, Hohmann AG. Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia. Neuropharmacology. 54: 161-71. PMID 17714742 DOI: 10.1016/J.Neuropharm.2007.07.006  0.376
2007 Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. British Journal of Pharmacology. 152: 765-77. PMID 17572696 DOI: 10.1038/Sj.Bjp.0707333  0.77
2007 Hohmann AG. Inhibitors of monoacylglycerol lipase as novel analgesics. British Journal of Pharmacology. 150: 673-5. PMID 17293886 DOI: 10.1038/sj.bjp.0707153  0.444
2007 Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, Hohmann AG. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. British Journal of Pharmacology. 150: 153-63. PMID 17160008 DOI: 10.1038/Sj.Bjp.0706984  0.477
2007 Rahn E, Hohmann A. 289 CANNABINOIDS SUPPRESS CHEMOTHERAPY-EVOKED PAINFUL PERIPHERAL NEUROPATHY THROUGH SPINAL SITES OF ACTION European Journal of Pain. 11: S128-S128. DOI: 10.1016/J.Ejpain.2007.03.304  0.727
2007 Hohmann A, Rahn E, Maxwell K, Zvonok A, Makriyannis A. 276 SELECTIVE ACTIVATION OF CANNABINOID CB2 RECEPTORS SUPPRESSES CHEMOTHERAPEUTIC NEUROPATHY EVOKED BY PACLITAXEL AND VINCRISTINE ADMINISTRATION European Journal of Pain. 11: S122-S122. DOI: 10.1016/J.Ejpain.2007.03.291  0.733
2007 Gutierrez T, Crystal J, Maxwell K, Zvonok A, Makriyannis A, Hohmann A. 272 SELF-ADMINISTRATION OF A CANNABINOID CB2 AGONIST IN AN ANIMAL MODEL OF NEUROPATHIC PAIN European Journal of Pain. 11: S120-S120. DOI: 10.1016/J.Ejpain.2007.03.287  0.387
2006 Hohmann AG, Suplita RL. Endocannabinoid mechanisms of pain modulation. The Aaps Journal. 8: E693-708. PMID 17233533 DOI: 10.1208/aapsj080479  0.418
2006 LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. The Journal of Pharmacology and Experimental Therapeutics. 319: 1051-61. PMID 16997973 DOI: 10.1124/Jpet.106.111385  0.398
2006 Connell K, Bolton N, Olsen D, Piomelli D, Hohmann AG. Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia. Neuroscience Letters. 397: 180-4. PMID 16378681 DOI: 10.1016/j.neulet.2005.12.008  0.428
2006 Suplita RL, Gutierrez T, Fegley D, Piomelli D, Hohmann AG. Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology. 50: 372-9. PMID 16316669 DOI: 10.1016/J.Neuropharm.2005.10.007  0.425
2005 Walker JM, Hohmann AG. Cannabinoid mechanisms of pain suppression. Handbook of Experimental Pharmacology. 509-54. PMID 16596786 DOI: 10.1007/3-540-26573-2-17  0.36
2005 Hohmann AG, Neely MH, Piña J, Nackley AG. Neonatal chronic hind paw inflammation alters sensitization to intradermal capsaicin in adult rats: a behavioral and immunocytochemical study. The Journal of Pain : Official Journal of the American Pain Society. 6: 798-808. PMID 16326368 DOI: 10.1016/j.jpain.2005.07.009  0.685
2005 Hohmann AG. A cannabinoid pharmacotherapy for chemotherapy-evoked painful peripheral neuropathy. Pain. 118: 3-5. PMID 16203094 DOI: 10.1016/j.pain.2005.07.007  0.376
2005 Suplita RL, Farthing JN, Gutierrez T, Hohmann AG. Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. Neuropharmacology. 49: 1201-9. PMID 16129456 DOI: 10.1016/j.neuropharm.2005.07.007  0.445
2005 Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D. An endocannabinoid mechanism for stress-induced analgesia. Nature. 435: 1108-12. PMID 15973410 DOI: 10.1038/Nature03658  0.608
2004 Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG. Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. Journal of Neurophysiology. 92: 3562-74. PMID 15317842 DOI: 10.1152/Jn.00886.2003  0.701
2004 Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. The Journal of Pharmacology and Experimental Therapeutics. 308: 446-53. PMID 14610224 DOI: 10.1124/Jpet.103.060079  0.508
2003 Gutierrez T, Nackley AG, Neely MH, Freeman KG, Edwards GL, Hohmann AG. Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. Brain Research. 987: 176-85. PMID 14499961 DOI: 10.1016/S0006-8993(03)03324-9  0.693
2003 Crystal JD, Maxwell KW, Hohmann AG. Cannabinoid modulation of sensitivity to time. Behavioural Brain Research. 144: 57-66. PMID 12946595 DOI: 10.1016/S0166-4328(03)00062-7  0.373
2003 Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 119: 747-57. PMID 12809695 DOI: 10.1016/S0306-4522(03)00126-X  0.732
2003 Nackley AG, Suplita RL, Hohmann AG. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 117: 659-70. PMID 12617970 DOI: 10.1016/S0306-4522(02)00870-9  0.716
2002 Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chemistry and Physics of Lipids. 121: 173-90. PMID 12505699 DOI: 10.1016/S0009-3084(02)00154-8  0.48
2000 Hohmann AG, Herkenham M. Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse (New York, N.Y.). 37: 71-80. PMID 10842353 DOI: 10.1002/(SICI)1098-2396(200007)37:1<71::AID-SYN8>3.0.CO;2-K  0.518
1999 Hohmann AG, Tsou K, Walker JM. Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord: comparison with morphine. Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica. 20: 1132-6. PMID 11216448  0.379
1999 Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K. The neurobiology of cannabinoid analgesia. Life Sciences. 65: 665-73. PMID 10462067 DOI: 10.1016/S0024-3205(99)00289-1  0.368
1999 Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience. 92: 1171-5. PMID 10426476 DOI: 10.1016/S0306-4522(99)00220-1  0.581
1999 Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America. 96: 5780-5. PMID 10318961 DOI: 10.1073/Pnas.96.10.5780  0.596
1999 Hohmann AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience. 90: 923-31. PMID 10218792 DOI: 10.1016/S0306-4522(98)00524-7  0.522
1999 Hohmann AG, Briley EM, Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Research. 822: 17-25. PMID 10082879 DOI: 10.1016/S0006-8993(98)01321-3  0.61
1999 Hohmann AG, Tsou K, Walker JM. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. Journal of Neurophysiology. 81: 575-83. PMID 10036261 DOI: 10.1152/Jn.1999.81.2.575  0.358
1998 Strangman NM, Patrick SL, Hohmann AG, Tsou K, Walker JM. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Research. 813: 323-8. PMID 9838180 DOI: 10.1016/S0006-8993(98)01031-2  0.335
1998 Hohmann AG, Herkenham M. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. Neuroscience Letters. 252: 13-6. PMID 9756347 DOI: 10.1016/S0304-3940(98)00534-5  0.627
1996 Tsou K, Lowitz KA, Hohmann AG, Martin WJ, Hathaway CB, Bereiter DA, Walker JM. Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience. 70: 791-8. PMID 10627219  0.436
1996 Martin WJ, Hohmann AG, Walker JM. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 6601-11. PMID 8815936  0.371
1992 Hohmann AG, Matsumoto RR, Hemstreet MK, Patrick SL, Margulies JE, Hammer RP, Walker JM. Effects of 1,3-di-o-tolylguanidine (DTG), a sigma ligand, on local cerebral glucose utilization in rat brain. Brain Research. 593: 265-73. PMID 1450934 DOI: 10.1016/0006-8993(92)91317-8  0.527
Show low-probability matches.